NEDD4L encodes an E3 ubiquitin protein ligase — an enzyme that tags specific proteins for degradation by labelling them with ubiquitin chains. Its most studied target is ENaC, the epithelial sodium channel¹¹ ENaC, the epithelial sodium channel
ENaC controls sodium reabsorption in the kidney collecting duct and is a major determinant of blood volume and blood pressure. NEDD4L ubiquitinates ENaC subunits, marking them for removal from the cell surface. When NEDD4L function falls, ENaC expression rises, more sodium is retained, and blood pressure climbs — the same mechanism that underlies Liddle syndrome, a rare monogenic form of hypertension caused by loss-of- function mutations in ENaC that escape NEDD4L targeting.

Beyond the kidney, NEDD4L is expressed broadly including in the brain, where it ubiquitinates substrates involved in neurodevelopment. It is this neurodevelopmental expression that connects the gene to the rs12606138 signal — a chromosomal 18q locus that has appeared in multiple independent linkage and association studies of developmental dyslexia and general reading ability.

The Mechanism

rs12606138 is an intronic variant in NEDD4L at position 58,326,712 (GRCh38, chr18q21.31). Intronic variants do not change the protein sequence directly, but can affect splicing efficiency, alter exon inclusion, or change regulatory element binding, thereby modulating the amount or isoform composition of NEDD4L protein produced. The precise molecular mechanism by which this variant influences reading ability has not been characterised, and it is possible that rs12606138 is itself a [tag SNP | a marker in linkage disequilibrium with a nearby causal variant rather than the functional change itself] for a functional change elsewhere in the locus.

NEDD4L has 43 exons and produces multiple isoforms expressed in different tissues. Brain-specific isoforms regulate neuronal ubiquitination processes including SMAD2/3 and TGF-β signalling pathways relevant to neuronal migration and cortical development — the same developmental processes disrupted in classical dyslexia neuropathology (ectopias, cortical microgyria).

The Evidence

The association between the chr18q NEDD4L locus and dyslexia was first established through linkage. Six independent studies reported linkage to a broad ~40 Mb region spanning 18p11.2 to 18q12.2 for developmental dyslexia or general reading ability, with NEDD4L identified as one of three candidate genes²² Six independent studies reported linkage to a broad ~40 Mb region spanning 18p11.2 to 18q12.2 for developmental dyslexia or general reading ability, with NEDD4L identified as one of three candidate genes
alongside MC5R and DYM.

The association was then refined to specific variants. In a German dyslexia case-control study of 388 cases and 364 controls, the major A allele of rs12606138 showed risk association with dyslexia (OR 1.35, 95% CI 1.0–1.7, p=0.017)³³ the major A allele of rs12606138 showed risk association with dyslexia (OR 1.35, 95% CI 1.0–1.7, p=0.017)
The variant was in strong LD with rs8094327, suggesting both tag the same causal signal. Notably, the association replicated in a German cohort a signal originally detected in English-speaking populations, indicating the locus acts across linguistic backgrounds — suggesting the biological effect is on neural reading circuitry rather than language-specific learning.

The 2016 Scientific Reports meta-analysis expanded this work with additional German subjects, further supporting the chromosome 18 NEDD4L region contribution to reading ability variance, though the effect at this specific variant remains modest (explained variance < 1%).

The G allele of rs12606138 appears to be the protective minor allele in European and African populations (~18–20%), and is even rarer in East Asian populations (~7%). The major A allele — carried by ~67% of Europeans as homozygotes — is the allele associated with increased dyslexia susceptibility in the German study. Effect sizes are modest: OR 1.35 at the population level, translating to a small absolute risk increase, consistent with a polygenic contribution to a complex neurodevelopmental trait.

Practical Implications

Dyslexia is a highly polygenic trait — hundreds of variants each contribute a fraction of a percent of variance. rs12606138 is one signal among many, and having the AA genotype does not predict dyslexia; it slightly shifts a population-level probability. The variant's practical value lies in raising awareness of the genetic architecture of reading difficulty and in research contexts for stratifying cohorts.

For cardiovascular health, NEDD4L's canonical role in ENaC-mediated sodium regulation means variants in this gene can affect salt sensitivity and blood pressure. While rs12606138 specifically has been studied in dyslexia genetics rather than blood pressure GWAS, the gene's expression profile and ubiquitin ligase function remain relevant to renal sodium handling. Monitoring blood pressure and limiting dietary sodium intake is prudent given this gene's established role in the pathway.

Interactions

rs12606138 is in strong linkage disequilibrium with rs8094327, a second NEDD4L intronic variant ~30 kb upstream, and the two variants likely tag the same functional signal. Considering both together does not independently add information beyond one of them.

The chr18q dyslexia locus shows independent signals from chromosome 6p (DCDC2, KIAA0319) and chromosome 3p (ROBO1) — the three most replicated dyslexia linkage regions. These loci appear to contribute independently, with some evidence of additive effects in polygenic score analyses.

IL1RAPL2¹¹ IL1RAPL2
interleukin-1 receptor accessory protein-like 2; gene ID 26280, located at Xq22.3 is a member of the IL-1 receptor superfamily expressed almost exclusively in the central nervous system. Unlike most IL-1 receptor family members that participate in immune signaling, IL1RAPL2 functions as a synaptic adhesion molecule²² synaptic adhesion molecule
a protein that bridges presynaptic and postsynaptic membranes to organize and stabilize connections between neurons — its primary job is building and maintaining connections between neurons, not immune regulation. The gene spans more than a megabase of the X chromosome (Xq22.3) and is closely related to IL1RAPL1, which is an established cause of X-linked cognitive disability and autism when deleted or mutated.

The rs12688128 variant is an intronic substitution (T→A) with no known functional consequence at the protein level. It appears in only one publication: a 2007 Thai study examining genetic susceptibility to thyrotoxic hypokalaemic periodic paralysis³³ thyrotoxic hypokalaemic periodic paralysis
THPP: episodic muscle weakness triggered by excess thyroid hormone, especially in hyperthyroid Asian men; thought to involve potassium shifts into muscle cells.

The Mechanism

IL1RAPL2 protein interacts trans-synaptically with PTPδ⁴⁴ PTPδ
protein tyrosine phosphatase delta, expressed on presynaptic axons; a synaptic organizer that pairs with postsynaptic proteins to specify synapse type and location on the presynaptic axon and with RhoGAP2 in the postsynaptic density. Together, this complex drives the formation of excitatory synapses and dendritic spines — the structural basis of learning and memory. Mouse studies show that Il1rapl2 is expressed in the nervous system from embryonic day 12.5 onward, consistent with a role in circuit assembly during early brain development.

The rs12688128 variant sits within an intron of IL1RAPL2, and no study has demonstrated that it alters splicing, expression, or protein function. Its CADD score of 0.376 and GERP score of −2.76 both indicate low evolutionary constraint and a low predicted functional impact — meaning this specific nucleotide position is not under strong purifying selection. The most plausible interpretation is that rs12688128 is a population-frequency marker in linkage disequilibrium with another variant elsewhere in the Xq22 region that might have functional relevance.

The Evidence

The single study linking rs12688128 to disease is Jongjaroenprasert et al. 2008⁵⁵ Jongjaroenprasert et al. 2008
"Association of genetic variants in GABRA3 gene and thyrotoxic hypokalaemic periodic paralysis in Thai population." Clin Endocrinol (Oxf) 68:646-51. This group used pooled DNA microarrays (50 THPP cases vs 50 hyperthyroid controls) and identified two SNPs — rs750841 and rs12688128 — that together formed a haplotype with a relative risk of 19 (P<0.0002) for THPP. The paper described both as "GABRA3 variants," but dbSNP places rs12688128 in the IL1RAPL2 intron at chrX:104,747,771, approximately 47 Mb centromeric from GABRA3 at chrX:152,297,246. Whether the original grouping reflects a genomic annotation error, linkage disequilibrium misclassification, or another explanation has not been clarified in subsequent literature.

Critically, this finding was not replicated in a Korean cohort⁶⁶ not replicated in a Korean cohort
Park et al. 2016, Endocrinol Metab (Seoul): 48 TPP cases vs 48 non-TPP Graves disease controls; GABRA3 polymorphisms showed OR 1.83, P=0.41 — not significant. The Korean study used a different population and different methodology, so the null result cannot definitively refute the Thai finding, but it means the association has failed its first replication attempt.

A separate reproductive biology connection comes from a 2025 bovine embryo study finding that IL1RAPL2 shows sex-biased differential exon usage in early blastocysts⁷⁷ sex-biased differential exon usage in early blastocysts
Shi et al. 2025, Cell Biosci: male and female bovine embryos activate IL1RAPL2 in sex-specific splice patterns as early as the blastocyst stage. This suggests the IL1RAPL2 locus participates in sex-specific transcriptional programs during early embryo development — relevant context for a variant on the X chromosome that is hemizygous in males and heterozygous in females.

Practical Actions

Because rs12688128 is an intronic variant with no known functional effect on IL1RAPL2 protein, and its only disease association (THPP) is based on a single small unreplicated study, clinical action at this locus is limited. Thyrotoxic hypokalaemic periodic paralysis occurs almost exclusively in the setting of hyperthyroidism (most commonly Graves disease) and resolves when thyroid function is normalized — making the genetic risk modifier of secondary importance compared to thyroid status itself.

For carriers of the A allele who are also hyperthyroid or have Graves disease, awareness that periodic paralysis episodes can occur — and can be severe enough to require emergency potassium supplementation — is the most actionable piece of information from this locus given current evidence.

Interactions

The Thai study identified rs12688128 in combination with rs750841 (an intronic GABRA3 variant). The combined haplotype showed a much larger association than either SNP alone (RR=19), suggesting potential epistatic or haplotype-level effects. GABRA3 encodes the alpha-3 subunit of the GABA-A receptor, which has documented roles in thyroid hormone sensitivity of skeletal muscle ion channels. If the association is genuine, the combination of rs750841 (GABRA3) and rs12688128 (IL1RAPL2) may tag a chromosomal haplotype whose functional variant has not yet been identified. The interaction should not be treated as established without replication.

TYK2 is the most genetically validated drug target in autoimmune disease today. Its pseudokinase (JH2) domain — the regulatory scaffold that controls the adjacent catalytic domain — is a hotspot for naturally occurring protective variants that reduce IL-12, IL-23, and type I interferon signaling without eliminating immune function. The Ile684Ser substitution (rs12720356) is the third and most common of three independent protein-coding protective signals in TYK2, and it provides some of the clearest evidence yet that TYK2 JH2 function is directly tunable by single amino acid changes.

Unlike rs34536443 (p.Pro1104Ala), which operates at the interface that couples the JH2 domain to the kinase (JH1) domain, Ile684Ser sits within the N-lobe of JH2 at a position that positions the αC helix for productive regulation of JH1. Replacing the rigid, hydrophobic isoleucine with a small, polar serine partially disrupts this structural arrangement — reducing but not abolishing TYK2's positive regulatory capacity. The net result is a hypomorphic TYK2 that retains sufficient antiviral and homeostatic signaling while measurably blunting the inflammatory amplification loops that drive autoimmune tissue damage.

The Mechanism

TYK2 mediates cytokine signaling downstream of the IL-12 receptor (activating JAK2-STAT4), IL-23 receptor (activating STAT3/STAT4), and type I interferon receptors IFNAR1/2 (activating JAK1-STAT1-STAT2). The JH2 pseudokinase domain acts as an allosteric regulator of the JH1 kinase domain — it both autoinhibits basal activity and potentiates the response to cytokine- driven activation.

Cytrzak-Gorczak et al. (2018)¹¹ Cytrzak-Gorczak et al. (2018) demonstrated directly in human blood that I684S reduces IL-12-stimulated STAT4 phosphorylation²² STAT4 phosphorylation
STAT4 is a transcription factor activated by IL-12 signaling that drives Th1 differentiation and IFN-γ production; reduced pSTAT4 means blunted IL-12-driven T cell polarization toward the Th1 inflammatory phenotype in CD4+ and CD8+ memory T cells. Critically, this reduction was measurable in skin-homing CLA+³³ CLA+
Cutaneous lymphocyte- associated antigen (CLA) marks T cells that home preferentially to skin, making them the relevant effector population in psoriasis T cells — the very immune cell subset responsible for psoriatic inflammation. Type I IFN-α signaling (STAT1/STAT2 pathway) is preserved because the JAK partner can compensate for reduced TYK2 JH2 regulatory capacity in that signaling context.

Fine-mapping of the TYK2 locus⁴⁴ Fine-mapping of the TYK2 locus confirmed that I684S, A928V (rs35018800), and P1104A (rs34536443) sit on three different haplotype backgrounds, establishing their independence. Conditional analysis shows that even after accounting for the stronger P1104A and A928V signals, I684S retains an independent protective effect (OR 0.86, P=4.6×10⁻⁷ for RA), confirming it is a genuine causal variant rather than a tag for the others.

The Evidence

The foundational genetic evidence comes from Diogo et al. (2015)⁵⁵ Diogo et al. (2015), who combined Immunochip dense genotyping, Exomechip genotyping, and targeted exon sequencing across 23,092 RA case/control + 18,409 additional samples. Three independent TYK2 coding signals emerged: P1104A (OR 0.66, P=2.3×10⁻²¹), A928V (OR 0.53, P=1.2×10⁻⁹), and I684S (OR 0.86, P=4.6×10⁻⁷). The same three variants also independently protected against SLE in the same study, supporting their pan-autoimmune relevance.

For psoriasis specifically, Sigurdardottir et al. (2018)⁶⁶ Sigurdardottir et al. (2018) provided functional cellular evidence: the I684S C allele significantly reduced STAT4 phosphorylation following IL-12 stimulation, with the effect measurable in skin-homing memory T cells — a finding that bridges the genetic association to the cellular mechanism responsible for plaque formation.

The meta-analysis by Lee and Bae (2016)⁷⁷ meta-analysis by Lee and Bae (2016), pooling 16,335 patients across 12 studies, confirmed protection for autoimmune rheumatic diseases in Caucasians (OR 0.812, 95% CI 0.661–0.997), though not in Asian populations — consistent with the variant's low frequency in East Asian ancestries. A 2019 study of Mexican patients with SLE⁸⁸ 2019 study of Mexican patients with SLE found strong protection at rs12720356 (OR 0.308 for childhood-onset, OR 0.250 for adult-onset), consistent with the Iberian origin of the C allele in admixed Latin American populations.

Practical Implications

With a European minor allele frequency of approximately 8%, I684S is more common than either A928V (~0.8%) or P1104A (~4%), making it the most population-accessible of the three independent TYK2 protective coding variants. About 15% of Europeans carry at least one C allele at rs12720356. Unlike P1104A — where the pharmacological copy (deucravacitinib) provided indirect evidence for a cancer immune-surveillance trade-off — no analogous cancer-risk signal has been reported for I684S carriers in the published literature.

For heterozygous AC carriers and for the rare CC homozygotes, this variant is relevant in the same clinical contexts as other TYK2 protective alleles: autoimmune workup interpretation, biologic therapy consideration, and family-history counseling for RA, SLE, psoriasis, and T1D. If a TYK2 inhibitor such as deucravacitinib is prescribed, the I684S allele contributes an independent layer of baseline TYK2 attenuation that a prescriber should be aware of.

Interactions

rs12720356 is one of three independent TYK2 protective coding variants confirmed by haplotype analysis to reside on separate haplotype backgrounds (Diogo et al. 2015). The other two are rs34536443 (P1104A, MAF ~4% in Europeans) and rs35018800 (A928V, MAF ~0.8% in Europeans). Individuals carrying C alleles at more than one of these three loci have multiple independent layers of TYK2 JH2 attenuation.

rs2304256 (V362F) — also in TYK2 — operates through a completely different mechanism (exon 8 splicing and FERM domain receptor binding), and fine-mapping has resolved⁹⁹ fine-mapping has resolved that the rs2304256 association signal in SLE and RA GWAS is largely driven by imperfect linkage disequilibrium with the actual causal coding variants, including I684S. The two variants are functionally and genetically independent.

Beyond TYK2, the I684S protective effect acts within the same autoimmune genetic architecture as PTPN22 (rs2476601, T cell receptor threshold) and CTLA4 (rs3087243, costimulation threshold) — variants that modulate T cell activation at different checkpoints and likely confer additive protection when co-inherited with protective TYK2 alleles.

The TRAF3IP2 gene encodes Act1 (also called CIKS — Connection to IKK and Stress-activated protein kinase), the essential scaffolding protein¹¹ the essential scaffolding protein
Act1 is recruited to the cytoplasmic domain of the IL-17 receptor upon IL-17A or IL-17F binding, bridging receptor activation to downstream NF-κB and MAP kinase inflammatory signaling in the IL-17 pathway. When genome-wide association studies scanned the locus looking for the single strongest statistical signal for psoriatic arthritis, rs13190932 — encoding the R74W (Arg74Trp) amino acid substitution in Act1 — emerged as the top hit: P = 8.56 × 10⁻¹⁷, odds ratio 1.83 in the combined sample of over 4,700 individuals of European descent. This is one of the most significant non-HLA association signals in psoriatic arthritis genetics.

The Mechanism

R74W changes arginine to tryptophan at position 74 of Act1, located in the N-terminal region of the protein near its TRAF-binding domain. Critically, functional assays show that R74W does not disrupt TRAF6 binding²² R74W does not disrupt TRAF6 binding
Full-length Act1 constructs carrying R74W showed TRAF6 binding comparable to wild-type in mammalian two-hybrid assays — in sharp contrast to the D10N variant (rs33980500) which loses ~90% of TRAF6-binding capacity. The variant is therefore not itself the mechanistic driver of disease: its disease association derives primarily from strong linkage disequilibrium³³ strong linkage disequilibrium
R²=0.88, D'=0.96 with rs33980500 in European populations, meaning rs13190932-A and rs33980500-T are nearly always inherited together on the same haplotype with the functionally causal D10N variant (rs33980500).

However, the rs13190932 locus carries independent information beyond simple LD tagging. Haplotype analysis in 2,077 PsA cases and 2,648 controls revealed that a four-SNP haplotype including both rs13190932 and rs33980500 carries an odds ratio of 2.7 for psoriatic arthritis⁴⁴ a four-SNP haplotype including both rs13190932 and rs33980500 carries an odds ratio of 2.7 for psoriatic arthritis
This four-SNP haplotype is substantially more predictive than either variant alone, suggesting that regulatory or structural effects from multiple alleles act in concert at this locus. Importantly, rs33980500 (D10N) appears on an additional rarer haplotype background that does not carry rs13190932-A; rs13190932 tracks a subset of the haplotype space that may be particularly enriched for joint (arthritis) versus skin-only (psoriasis vulgaris) disease manifestation.

The Evidence

The initial discovery cohort was 609 German individuals with psoriatic arthritis and 990 controls⁵⁵ 609 German individuals with psoriatic arthritis and 990 controls
Discovery was followed by replication across 6 additional European cohorts totaling 5,488 individuals; combined analysis: OR=1.83 (95% CI 1.59–2.12), P=8.56×10⁻¹⁷. The PsA association (P=8.56×10⁻¹⁷) is approximately 10,000-fold more significant than the psoriasis vulgaris association at the same SNP (P=1.95×10⁻³), suggesting that while rs13190932 tags a shared TRAF3IP2 risk haplotype, the haplotype it tracks is particularly enriched for patients who develop joint involvement.

The variant is essentially monomorphic in East Asian populations⁶⁶ essentially monomorphic in East Asian populations
Both rs13190932 and rs33980500 showed no polymorphism in Han Chinese cohorts studied for Behçet's disease and Vogt-Koyanagi-Harada syndrome — consistent with near-zero allele frequency in East Asian populations in gnomAD. This mirrors the marked ancestral stratification seen in psoriatic arthritis genetics more broadly, where European-derived loci often show minimal variation in East Asian populations that have a distinct psoriasis genetic architecture.

Beyond psoriatic arthritis and psoriasis, rs13190932 has been evaluated across the spectrum of IL-17-pathway autoimmune disease. In systemic lupus erythematosus, all three TRAF3IP2 coding variants (rs33980500, rs13190932, rs13193677) associate with pericarditis development⁷⁷ associate with pericarditis development
Italian cohort of SLE patients: all three TRAF3IP2 SNPs associated with pericarditis; rs13190932-A specifically associated with malar rash (OR=2.14, P=0.041), suggesting the haplotype marked by rs13190932 influences IL-17-mediated vascular and mucocutaneous inflammation across autoimmune contexts.

Practical Implications

Because R74W is not itself the mechanistic driver of disease — its signal derives from LD with D10N — the clinical and practical implications of rs13190932 are best understood as a read-out of the broader TRAF3IP2 risk haplotype. Individuals carrying the A risk allele have substantially elevated psoriatic arthritis risk and warrant the same monitoring and management considerations as D10N (rs33980500) carriers.

The primary practical value of genotyping rs13190932 is as an LD sentinel⁸⁸ LD sentinel
Sentinel variants mark disease association peaks in GWAS; they provide risk stratification even when they are not themselves the causal variants, because they reliably travel with the causal variant in the population for the full TRAF3IP2 risk haplotype. If a genome report includes rs13190932 but not rs33980500, the A allele at rs13190932 provides robust risk stratification for psoriatic arthritis at this locus.

For biologic therapy decisions, the same considerations as D10N apply: the TRAF3IP2 risk haplotype marked by rs13190932 signals impaired canonical IL-17→TRAF6→NF-κB signaling. Anti-IL-17 agents (secukinumab, ixekizumab, brodalumab) and anti-IL-23 agents (guselkumab, risankizumab) each target distinct points in the upstream pathway and may merit consideration relative to anti-TNF agents depending on joint versus skin disease predominance.

Interactions

rs13190932 and rs33980500 (D10N) are in very high LD (R²=0.88) and almost always travel together on the same haplotype. The four-SNP haplotype that includes both variants, plus rs13210247 and rs13196377, carries an OR of 2.7 for psoriatic arthritis — substantially higher than either coding variant alone, indicating additive haplotype effects likely from regulatory variants in non-coding intervals.

The rs13190932 risk haplotype operates within the broader IL-17/Th17 axis. HLA-C rs12191877⁹⁹ HLA-C rs12191877
tags HLA-Cw*0602, the dominant psoriasis susceptibility allele; confers ~30-fold increased risk for type I psoriasis via impaired self-tolerance at the T-cell level creates a dual-hit with the TRAF3IP2 locus: impaired immunological tolerance upstream (HLA) combined with altered IL-17 adaptor signaling downstream (TRAF3IP2). Carriers of both loci likely face synergistic psoriasis and psoriatic arthritis risk that warrants early specialist engagement.

Your immune system's type I interferon alarm — orchestrated by Interferon Regulatory Factor 5 (IRF5) — is one of the most powerful switches in human innate immunity. When this switch runs too loud and too long, the result is chronic inflammatory damage seen in systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, and systemic sclerosis. rs13245639 sits in the 5' upstream regulatory region of IRF5 at chromosome 7, position 128,927,756 (GRCh38), and represents one of the most functionally characterized cis-regulatory variants at this locus. In near-perfect linkage disequilibrium (r²=0.97) with the established protective tag SNP rs729302, rs13245639 is not merely a proxy — its T allele directly shows allele-specific transcription factor binding¹¹ transcription factor binding
Detected by electrophoretic mobility shift assay (EMSA): a technique that reveals whether nuclear proteins bind differently to two alleles of a DNA sequence and lower IRF5 expression in reporter gene assays, making it a functional candidate for the protective effect and arguably a sharper tag on whole-genome sequencing platforms.

The Mechanism

IRF5 operates as a master transcription factor for type I interferon (IFN-α/β) production and for proinflammatory cytokine secretion (IL-12, IL-6, TNF-α) in innate immune cells — monocytes, macrophages, plasmacytoid dendritic cells, and B cells. Overexpression of IRF5 drives the sustained interferon signature characteristic of autoimmune flares. The rs13245639 variant lies within the 5' upstream regulatory architecture of IRF5, approximately 1.15 kilobases from the rs729302 anchor SNP within the same haplotype block.

The functional work by Alonso-Perez et al. 2013²² Alonso-Perez et al. 2013
Identification of three new cis-regulatory IRF5 polymorphisms: in vitro studies. Arthritis Research & Therapy, 2013 screened 26 candidate cis-regulatory SNPs — selected from 54 genotyped variants across the IRF5 5' region — for functional activity in lymphoblastoid cells. rs13245639 emerged as one of only seven that showed reproducible allele-specific differences in EMSA and one of three (alongside rs729302 itself and an indel at rs11269962) that passed both EMSA and reporter gene assay criteria. In EMSA experiments, the T allele produced a specific band slowdown (band shift) compared with the C allele, indicating that one or more nuclear proteins bind preferentially to the T-allele sequence. The causal transcription factor was not identified — high-throughput bioinformatic tools performed poorly on this region — but the binding difference is reproducible.

In luciferase reporter gene assays, constructs carrying the major C allele of rs13245639 showed significantly higher expression than constructs with the minor T allele (P<0.05, Wilcoxon matched-pairs test). This is the functionally coherent direction: the C allele drives higher IRF5 transcription, the T allele dampens it. Since the T allele travels with the rs729302-C protective haplotype at r²=0.97, the protective biology is mechanistically consistent — the T allele reduces IRF5 output, softening the interferon alarm and lowering autoimmune drive.

The near-perfect LD (r²=0.97) between rs13245639 and rs729302 in European cohorts means the two variants capture essentially the same haplotype signal. On consumer genotyping arrays that include rs729302, this adds little incremental information. However, on whole-genome sequencing platforms — where both sites are called with equal fidelity — rs13245639 may provide superior functional interpretation because its allele-specific expression difference is directly demonstrated, whereas rs729302 remains a functional tag whose causal status is less certain. The rs729302 signal is partly explained by LD with the CGGGG promoter indel; rs13245639 may tag the same underlying causal architecture from a different angle.

The Evidence

The foundational protective signal at the IRF5 5' locus was established in the landmark 14-cohort European SLE study by Ferreiro-Neira et al. 2007³³ Ferreiro-Neira et al. 2007
Ann Rheum Dis 2007 66:1338-41, which genotyped 1,383 SLE cases and 1,614 controls. Two independent signals emerged from the IRF5 locus: a 3' susceptibility signal (tagged by rs10488631, P<10⁻¹⁷) and an opposing 5' protective signal (tagged by rs729302, P<10⁻⁶). The protective signal persisted after conditioning on the susceptibility signal, establishing it as a genuine independent effect. Because rs13245639 is in r²=0.97 LD with rs729302, the T allele directly captures this protective signal.

In rheumatoid arthritis, a meta-analysis of five case-control studies⁴⁴ meta-analysis of five case-control studies
Han et al. 2009, J Rheumatol; 6,582 RA cases and 5,375 controls confirmed that the rs729302-tagged protective allele reduces RA risk (random-effects OR=0.889, 95% CI 0.803–0.977, P=0.015). By virtue of near-perfect LD, the rs13245639-T allele carries the same protective association in RA.

The functional significance of rs13245639 specifically — its EMSA band shift and its lower luciferase expression — was established in vitro by Alonso-Perez et al. 2013. While in vitro data alone constitute moderate rather than strong evidence for an individual SNP's causal role, the convergence with the strong epidemiological signal from rs729302 (which it tags at r²=0.97) and the mechanistically coherent direction (T allele = lower IRF5 = reduced autoimmune drive) supports a moderate-to-strong overall evidence rating for the protective biology of this locus.

Practical Implications

Carrying one or two copies of the T allele at rs13245639 indicates your IRF5 locus carries partial or full protective regulatory architecture in the 5' upstream region. This is the same biology captured by rs729302-C — if you have results from a genotyping array that includes rs729302, your rs13245639 interpretation is almost certainly concordant (r²=0.97 means fewer than 3% of people would show discordant genotypes between the two sites).

The protective effect is additive per T allele, consistent with the additive inheritance pattern seen at rs729302. Heterozygous CT individuals carry one buffered and one unbuffered copy of the IRF5 5' regulatory region; TT homozygotes carry the protective architecture on both chromosomes. Neither genotype guarantees freedom from autoimmune disease — the IRF5 locus is one component of a multigenic autoimmune risk architecture that includes HLA, PTPN22, STAT4, and other contributors. However, the T allele provides real, documented biological buffering of the interferon overactivation that underlies SLE and RA.

The most important context for this variant is the full IRF5 haplotype picture: individuals who carry rs13245639-T (no susceptibility at the 5' locus) alongside rs10488631-TT (no susceptibility at the 3' locus) have the most comprehensively protected IRF5 regulatory configuration currently characterized.

Interactions

rs13245639 is in near-perfect LD with rs729302 (r²=0.97) and travels on the same protective 5' haplotype block. For practical purposes, genotyping rs13245639 and rs729302 provides redundant information; however, on WGS data both are present and rs13245639's functional annotation makes it a useful confirmatory or primary tag.

The 5' protective haplotype tagged by rs13245639-T opposes the 3' susceptibility haplotype tagged by rs10488631 (documented separately). These two haplotype blocks are functionally independent — individuals can carry any combination of the two, and their net IRF5-driven autoimmune susceptibility reflects the additive contributions from both loci.

At the pathway level, IRF5 interacts with STAT4 (rs7574865), the signal transducer downstream of type I interferon. IRF5 drives IFN production; STAT4 amplifies cellular responsiveness to that IFN. rs13245639-T carriers who also carry the STAT4 non-risk genotype benefit from a dual buffer: reduced interferon production and reduced interferon amplification.

BLK (B-lymphoid tyrosine kinase)¹¹ BLK (B-lymphoid tyrosine kinase)
A Src-family non-receptor tyrosine kinase expressed almost exclusively in B cells and plasmacytoid dendritic cells encodes a kinase that plays a critical role in B-cell receptor (BCR) signaling and B-cell development. Acting as an accelerator for BCR-driven activation signals, BLK helps B cells respond to antigen stimulation — but crucially, it also participates in the central tolerance checkpoint²² central tolerance checkpoint
The process by which immature B cells that recognize self-antigens are eliminated or silenced in the bone marrow before they can cause harm that eliminates self-reactive B cells. The rs13277113 SNP sits in the promoter region upstream of the BLK transcription start site: the A risk allele reduces BLK mRNA levels in B-cell lines, and carriers show lower BLK expression³³ carriers show lower BLK expression
Pamuk et al. 2017 measured BLK mRNA in blood samples of 84 SLE patients: expression was 0.52× that of controls in circulating immune cells.

The Mechanism

BLK is a Src-family kinase⁴⁴ Src-family kinase
A family of non-receptor tyrosine kinases including Src, Fyn, Lck, and Lyn. BLK is the B-cell-specific member expressed at high levels in B cells from the pre-B cell stage onward. Within the B-cell receptor signaling complex, BLK phosphorylates downstream substrates that both activate B-cell responses to antigen and help establish negative selection of self-reactive clones. When BLK expression is reduced by the A allele, this tolerance mechanism is partially impaired: B cells that recognize self-antigens escape deletion more readily. The result is a subtle shift toward B-cell hyperactivation and increased autoantibody production⁵⁵ increased autoantibody production
Including anti-dsDNA and anti-Smith antibodies characteristic of SLE, and anti-SSA/SSB antibodies in Sjögren's syndrome, the hallmark of multiple systemic autoimmune diseases.

The variant is located at chromosome 8p23.1 in the FAM167A-BLK locus. Notably, the A allele at rs13277113 is also associated with increased expression of the neighboring gene C8orf13/FAM167A⁶⁶ increased expression of the neighboring gene C8orf13/FAM167A
The risk allele reduces BLK but increases FAM167A expression; the functional consequences of elevated FAM167A remain incompletely characterized, suggesting the regulatory region affects a shared promoter element.

The Evidence

The discovery GWAS⁷⁷ discovery GWAS
Hom G et al. 2008 — 1,311 SLE cases, 1,783 North American controls; replicated in 793 Swedish cases and 857 Swedish controls published in the New England Journal of Medicine identified rs13277113 as a genome-wide significant SLE susceptibility locus (OR=1.39, P=1×10⁻¹⁰). Crucially, the study also showed that the A allele correlated with reduced BLK mRNA levels in B-cell lines, providing direct mechanistic evidence linking a regulatory variant to altered gene expression to disease risk.

Subsequent meta-analyses have firmly established this association. A 2011 meta-analysis⁸⁸ 2011 meta-analysis
Fan et al. — 11,796 SLE cases and 20,271 controls across six studies found an overall A-allele OR of 1.42 with no publication bias and no heterogeneity, supporting a highly consistent effect. The largest 2017 meta-analysis⁹⁹ 2017 meta-analysis
Song and Lee — 17 studies, 22,701 cases, 36,365 controls confirmed OR=1.36 (P<1×10⁻⁸) consistent across Caucasian, Asian, and African populations. A broader autoimmune disease meta-analysis¹⁰¹⁰ broader autoimmune disease meta-analysis
Zeng et al. 2017 — 24 studies, 31,095 cases, 39,077 controls for rs13277113 covering SLE, RA, Sjögren's, and other conditions found rs13277113 A vs G: OR=1.33 (95% CI 1.27–1.39), with the strongest associations in Asian populations.

Beyond SLE, BLK rs13277113 is associated with systemic sclerosis¹¹¹¹ systemic sclerosis
Gourh P et al. 2009: 1,050 SSc cases and 694 controls (North American) + 589 SSc cases and 722 controls (Spanish) (OR=1.32 U.S., OR=1.20 combined), particularly with the limited cutaneous and anti-centromere antibody subsets. A French cohort meta-analysis¹²¹² meta-analysis
Coustet et al. 2011 — 6,078 individuals; strongest effect in diffuse cutaneous SSc (OR=1.27) found additive effects between BLK and BANK1 in driving systemic sclerosis risk.

Clinical observations add important nuance: a Turkish cohort study found that the GA genotype¹³¹³ GA genotype
Pamuk et al. 2017 — 84 SLE patients and 105 controls was present in 48.8% of SLE patients versus 31.4% of controls (p=0.035), and SLE patients with the GA genotype had significantly more disease flares¹⁴¹⁴ disease flares
Assessed by SELENA-SLEDAI flare index: 70% of GA carriers vs 37% of non-carriers experienced flares during follow-up.

Practical Implications

Carriers of the A allele — particularly AA homozygotes — have a modestly elevated lifelong background risk for B-cell-driven autoimmune diseases. The most important practical steps are recognizing the early warning signs and ensuring prompt diagnosis if symptoms emerge. The diseases associated with BLK variants — SLE, Sjögren's syndrome, and systemic sclerosis — are all manageable with modern treatments¹⁵¹⁵ manageable with modern treatments
Including hydroxychloroquine, low-dose corticosteroids, biologics (belimumab, rituximab), and immunomodulatory drugs when caught early, but can cause significant organ damage if untreated.

The genetic risk from rs13277113 is modest in absolute terms — most carriers will not develop autoimmune disease. However, it meaningfully shifts the probability calculation and warrants increased vigilance: unexplained joint pain, persistent fatigue, rashes (especially malar/butterfly rash), Raynaud's phenomenon, persistent dry eyes or mouth, and abnormal inflammatory markers all warrant autoimmune workup in risk-allele carriers.

There are no supplement or dietary interventions proven to counteract BLK-mediated B-cell dysregulation. The actions center on monitoring, early detection, and avoiding immune-modulating triggers where possible.

Interactions

The most clinically relevant epistatic interaction is with BANK1 rs10516487¹⁶¹⁶ BANK1 rs10516487
BANK1 R61H, a missense variant in a B-cell scaffold protein that promotes BCR hyperactivation. In a Mexican Latin-American cohort, individuals carrying risk alleles at both BLK rs13277113 and BANK1 rs10516487 showed an interaction OR of 2.36 (P<0.0001) for primary Sjögren's syndrome — substantially higher than either variant alone. An independent trans-ethnic meta-analysis¹⁷¹⁷ trans-ethnic meta-analysis
Génin et al. 2013 — 1,915 RA cases and 1,915 controls from France, Spain, and Japan found a gene-gene interaction between BLK rs13277113 and BANK1 rs3733197 in rheumatoid arthritis (P=0.037): in individuals with BLK GG genotype, the BANK1 G allele increased RA risk (OR=1.21). Both BLK and BANK1 converge on B-cell receptor signaling; their co-occurrence appears to push B-cell hyperactivation beyond what either variant achieves alone.

BLK risk alleles also show partial overlap¹⁸¹⁸ partial overlap
Both PTPN22 R620W and BLK rs13277113 independently predispose to SLE and RA through distinct B-cell and T-cell tolerance mechanisms with PTPN22 rs2476601 (R620W) in autoimmune disease architecture, though BLK specifically affects B-cell tolerance while PTPN22 affects both B-cell and T-cell receptor signaling thresholds.

Lipoprotein lipase (LPL) is the principal enzyme that clears triglyceride-rich lipoproteins¹¹ triglyceride-rich lipoproteins
Very low-density lipoproteins (VLDL) and chylomicrons — the particles that carry fat from the liver and intestine through the bloodstream from circulation. Most research into LPL genetics has focused on coding variants that change the protein itself. rs13702 works differently: it sits in the 3' untranslated region of the LPL gene, a stretch of mRNA that doesn't code for protein but acts as a regulatory landing pad for microRNAs. The variant's mechanism is one of the clearest examples of non-coding genetic regulation affecting a clinically important phenotype.

The Mechanism

The LPL 3' UTR at rs13702 contains a recognition element for microRNA-410 (miR-410). MicroRNAs are short non-coding RNA molecules that bind to target sequences in mRNA and suppress gene expression — they act as a molecular volume knob, turning down the amount of protein produced. When miR-410 binds its recognition element in the LPL 3' UTR, it reduces LPL mRNA translation, lowering the amount of lipoprotein lipase enzyme made.

The rs13702 T allele (the common reference sequence) preserves this binding site intact. miR-410 binds normally, and LPL expression is held under its natural degree of suppression. The C allele, which disrupts the miR-410 seed-sequence match²² seed-sequence match
The "seed" region of a microRNA is its 6–8 nucleotide core that determines target recognition. A single nucleotide change that disrupts complementarity at the seed is enough to abolish binding entirely, prevents miR-410 from binding. Without this brake, luciferase reporter assays³³ luciferase reporter assays
Laboratory experiments where the LPL 3'UTR is fused to a reporter gene — if the mRNA is suppressed, less light is produced. These assays demonstrated the T allele was suppressed 40% by miR-410 mimics, while the C allele was not suppressed at all showed that the T-allele LPL mRNA is reduced by approximately 40% when miR-410 is present, whereas the C-allele reporter is completely unaffected. The result is that C-allele carriers produce more LPL enzyme, clear triglycerides more efficiently, and generate more HDL cholesterol as a byproduct of lipolysis.

The Evidence

Richardson et al.⁴⁴ Richardson et al.
Richardson K et al. Gain-of-function lipoprotein lipase variant rs13702 modulates lipid traits through disruption of a microRNA-410 seed site. Am J Hum Genet, 2013 performed the definitive characterisation of this variant in a meta-analysis across ten population cohorts. Each copy of the C allele was associated with −0.060 mmol/L lower plasma triglycerides (p = 3.18 × 10⁻⁴²) and +0.041 mmol/L higher HDL cholesterol (p = 1.35 × 10⁻³²) — effects equivalent to roughly a 3–5% reduction in fasting triglycerides per allele copy. The study also showed that the lipid-lowering effect of the C allele was amplified in the presence of higher dietary polyunsaturated fat intake (p = 0.00153 for interaction), adding a dietary dimension to the gain-of-function biology.

The CARDIA study Tang et al.⁵⁵ Tang et al.
Tang W et al. Associations of LPL gene polymorphisms with longitudinal plasma lipid trends in young adults. Circ Cardiovasc Genet, 2010 followed 4,161 individuals for 20 years, finding that the C allele not only conferred lower triglycerides and higher HDL at baseline but also slowed the age-related trajectory of worsening lipids — the protective benefit accumulates over a lifetime.

The PREDIMED randomised controlled trial Corella et al.⁶⁶ Corella et al.
Corella D et al. MicroRNA-410 regulated lipoprotein lipase variant rs13702 is associated with stroke incidence and modulated by diet in the randomized controlled PREDIMED trial. Am J Clin Nutr, 2014 examined stroke incidence and found that T-allele homozygotes had elevated stroke risk compared to C-allele carriers. Crucially, assignment to a Mediterranean diet pattern eliminated this excess risk in T-allele carriers — a direct demonstration that dietary fat quality modifies the consequences of reduced LPL activity through this microRNA mechanism.

Dietary modulation was confirmed by Hammad et al.⁷⁷ Hammad et al.
Hammad et al. Common Variants in Lipid Metabolism-Related Genes Associate with Fat Mass Changes in Response to Dietary MUFA in Adults with Abdominal Obesity. J Nutr, 2019, who found that CC homozygotes on high-MUFA diets achieved significantly greater visceral fat reduction (−216 g vs. +17 g in TT carriers, p = 0.017), suggesting the protective effect of the C allele is potentiated by replacing saturated fat with monounsaturated fat.

The C allele frequency varies considerably by ancestry: approximately 29% in Europeans, 51% in Africans, 20% in East Asians, 24% in South Asians, and 30% in Latinos. Most individuals carry at least one C allele, but around 42% of the global population carries TT — the genotype with standard, unmodified LPL expression.

Practical Implications

This is a protective variant. C-allele carriers benefit from the gain-of-function effect automatically — they clear triglycerides more efficiently and maintain higher HDL. The evidence for TT homozygotes points to a meaningful advantage to optimising LPL activity through diet: replacing saturated fat with monounsaturated and polyunsaturated fats (Mediterranean-style dietary fat quality, not simply fat quantity) appears to partially compensate for the absence of the miR-410 disruption. Omega-3 polyunsaturated fatty acids (EPA and DHA) reduce VLDL secretion and upregulate LPL expression through PPAR-α — a mechanistically relevant intervention for T-allele carriers who lack the genetic braking relief of the C allele.

Interactions

rs13702 and rs264 (LPL intron 6) are both LPL regulatory variants but operate through distinct mechanisms: rs264 modulates intronic regulatory elements or splicing enhancers, while rs13702 specifically disrupts a post-transcriptional miRNA regulatory step. They may reside on independent haplotypes. The gain-of-function coding truncation rs328 (S447X) raises LPL activity through a different route (altered heparin-binding and clearance kinetics) and may combine additively with the rs13702 C allele. APOA5 variants (including rs662799 upstream of the gene) reduce LPL stimulation; TT carriers at rs13702 who also carry APOA5 risk alleles face a compounded deficit in triglyceride clearance capacity.

TYRP1 (tyrosinase-related protein 1) is a melanocyte-specific enzyme that sits at a critical junction in the eumelanin biosynthesis pathway. Inside melanosomes — the specialized organelles that produce and store pigment — TYRP1 catalyzes the oxidation of DHICA¹¹ DHICA
5,6-dihydroxyindole-2-carboxylic acid, a key intermediate in brown-black eumelanin production, while simultaneously stabilizing tyrosinase (the rate-limiting enzyme) and maintaining the structural integrity of the melanosome membrane itself. rs1408799 is an intronic variant in TYRP1 on chromosome 9p23 that modulates how much eumelanin — the brown-black pigment responsible for photoprotection — your melanocytes produce. The C allele is nearly fixed in Northern Europeans (frequency ~69%) but extremely rare in East Asians (~2%), reflecting its role in the adaptive depigmentation that occurred as populations moved to lower-UV environments.

The Mechanism

rs1408799 sits within an intron and does not directly alter the TYRP1 protein sequence. Its biological effect appears to be mediated through linkage disequilibrium with nearby functional variants — it is in strong LD (D'>0.7) with rs683 (a 3'UTR variant) and rs2733836, both of which are incorporated into forensic eye-color prediction models. The net effect of the C-allele haplotype is reduced eumelanin output: less brown-black pigment in irises, hair follicles, and skin. Reduced eumelanin shifts the melanocyte balance toward pheomelanin (the yellow-red pigment), lightening overall coloration and diminishing the natural photoprotective shield that dense eumelanin provides. Pheomelanin is a pro-oxidant that generates reactive oxygen species even without UV exposure²² Pheomelanin is a pro-oxidant that generates reactive oxygen species even without UV exposure
unlike eumelanin, which absorbs and dissipates UV energy harmlessly, meaning lower eumelanin does not merely reduce protection — it actively amplifies oxidative damage in skin and iris tissue.

The Evidence

The foundational evidence comes from an Icelandic genome-wide association study³³ Icelandic genome-wide association study
Sulem et al., Nature Genetics, 2007 with replication in additional Icelandic and Dutch participants. The C allele was associated with blue versus nonblue eyes (OR 1.41, p=1.5×10⁻⁹) and showed a suggestive association with blond versus brown hair. The study is also replicated in eye-color prediction research from forensic genetics, where rs1408799 is one of two TYRP1 variants included in pigmentation prediction tools alongside the major HERC2/OCA2 locus (rs12913832).

For melanoma, the same research group (Gudbjartsson et al., Nature Genetics, 2008⁴⁴ Gudbjartsson et al., Nature Genetics, 2008
2,121 melanoma cases, 40,000+ controls) found the C allele associated with cutaneous melanoma risk (OR 1.15, p=4.6×10⁻⁴), and critically, this association remained significant even after statistical adjustment for pigmentation phenotypes — suggesting that the C-allele haplotype's effect on melanoma risk is not entirely explained by lighter visible pigmentation alone. A nested case-control study in Caucasian women⁵⁵ nested case-control study in Caucasian women
Nan et al., 2009, 218 melanoma cases and 870 controls found a protective trend for the T allele (OR 0.77, 95% CI 0.60–0.98), though this did not survive Bonferroni correction. The overall body of evidence indicates a modest but real risk contribution from the C-allele haplotype, consistent with reduced eumelanin as a biological mechanism.

The population frequency pattern itself tells part of the story: the C allele rose from ~28% in African populations (which have the highest eumelanin levels) to ~69% in Europeans (who have lower photoprotection needs due to reduced UV at high latitudes). East Asian populations, who achieved light skin through different genes (SLC24A5, SLC45A2), show only ~2% C-allele frequency — an elegant example of convergent evolution where multiple genetic pathways reached similar phenotypic endpoints.

Practical Implications

This variant is an additive risk modifier: each C allele slightly reduces eumelanin production, shifts the balance toward lighter pigmentation, and modestly increases UV-induced melanoma risk. For CC homozygotes (the most common European genotype), the effect is most pronounced. For TT homozygotes, higher eumelanin provides a natural photoprotective advantage at this locus.

The practical take-away differs from "just use sunscreen" (a recommendation that applies to everyone). Carriers of one or two C alleles have a specific eumelanin deficit that increases their sensitivity to UV-induced oxidative DNA damage and their melanoma susceptibility beyond what visible skin tone alone would predict. The melanoma risk remaining after adjustment for pigmentation phenotypes means that even individuals who don't look especially light-skinned but carry CC at TYRP1 may face elevated risk. This makes genotype-informed photoprotection monitoring more valuable than relying on a clinician's visual assessment of skin type alone.

Interactions

The most significant documented interaction is between rs1408799 in TYRP1 and rs12913832 in HERC2. Pospiech et al. (2011)⁶⁶ Pospiech et al. (2011)
718 European participants, Journal of Human Genetics identified a novel synergistic (epistatic) interaction between these two loci specifically for green eye color determination. In individuals already homozygous for the blue-eye HERC2 allele (rs12913832:GG), TYRP1 rs1408799 modulates residual variation in iris color — explaining why some GG individuals have green rather than blue irises. This interaction is not captured by either variant alone and requires co-occurrence of specific alleles at both loci. The combination of HERC2 rs12913832 (the dominant blue-eye switch) and TYRP1 rs1408799 (a eumelanin volume dial) together create the conditions for green iris pigmentation.

TYRP1 also interacts with TYR (rs1042602), SLC45A2 (rs16891982), and IRF4 (rs12203592) in melanoma risk. Individuals carrying high-risk alleles at multiple pigmentation loci face compounding — not merely additive — risk increases that substantially exceed what any single variant predicts. The compound effect of low eumelanin from multiple independent genetic routes creates both phenotypic and oncological risk that warrants intensified dermatology surveillance beyond what any single test result would recommend.

Interleukin-1 alpha (IL-1α) is not just another pro-inflammatory cytokine — it is a unique alarmin¹¹ alarmin
An alarmin is a damage-associated molecular pattern (DAMP) that is released from dying or stressed cells to signal danger to the immune system before adaptive immunity activates. Unlike IL-1β, which must be actively processed by the inflammasome and secreted, IL-1α is constitutively produced as a precursor (pro-IL-1α) in virtually all nucleated cells and is released as an immediate alarm signal when cells are damaged. At rs17561, a single amino acid substitution at position 114 of the protein — alanine to serine — creates a very common hypomorphic form of IL-1α that releases roughly half as much cytokine into the extracellular space.

The Mechanism

Position 114 sits in the central linker region that joins the pro-domain to the mature cytokine domain of pro-IL-1α. Multi-species alignment shows this alanine is highly conserved across mammals, suggesting it is functionally important for protein handling. The A allele at rs17561 (on the plus strand) encodes serine at this position; the common C allele encodes alanine.

Wiggins et al. (2023, Immunology) characterised this variant functionally²² Wiggins et al. (2023, Immunology) characterised this variant functionally
The common IL1A single nucleotide polymorphism rs17561 is a hypomorphic mutation that significantly reduces interleukin-1α release from human blood cells. Immunology 168:459-472 using a recall-by-genotype design in the Cambridge BioResource. When whole blood from volunteers stratified by genotype was stimulated with LPS, AA homozygotes released approximately 50% less IL-1α than CC homozygotes, while IL-1β release was equivalent between groups. IL-1α transcript levels were identical across genotypes, ruling out a transcriptional mechanism. Protease cleavage assays with calpain, thrombin, elastase, and cathepsin B showed no difference between the Ala and Ser forms. The deficit appears to be post-translational: more Ser-form pro-IL-1α is retained within the cell rather than secreted. Transfected macrophage experiments confirmed that reduced secretion is caused directly by the amino acid substitution and not by confounding genetic variation in linkage disequilibrium.

The Evidence

Periodontitis. The Yin et al. (2016) meta-analysis of six case-control studies (336 cases, 366 controls)³³ Yin et al. (2016) meta-analysis of six case-control studies (336 cases, 366 controls)
Association between IL-1α rs17561 and IL-1β rs1143634 polymorphisms and periodontitis: a meta-analysis. Genet Mol Res 2016 found that the T allele (Ser form; called G/T in coding-strand notation, equivalent to C/A on the plus strand) is associated with significantly elevated periodontitis risk (OR = 1.50 per allele; OR = 1.57 for TC+TT carriers vs non-T carriers). The direction of effect — reduced IL-1α secretion correlating with worse periodontal disease — is counterintuitive at first glance but consistent with a model in which IL-1α provides essential mucosal barrier protection: insufficient IL-1α at gingival surfaces may impair bacterial sensing and the epithelial alarmin response, leaving subgingival biofilms inadequately controlled. It is worth noting that this meta-analysis was small (700 total participants) and findings across individual studies were not fully consistent.

Ankylosing spondylitis. The Sims et al. (2008) prospective meta-analysis, 2,675 AS cases and 2,592 controls across 12 centres in 10 countries⁴⁴ Sims et al. (2008) prospective meta-analysis, 2,675 AS cases and 2,592 controls across 12 centres in 10 countries
Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis 67:1305-9 identified rs17561 as one of three IL1A SNPs with strong association with AS susceptibility (p = 0.000019), estimating the population-attributable risk in Caucasians at 4–6% for the IL1A locus overall. Whether this reflects direct causality through reduced IL-1α alarmin signalling or tagging of adjacent functional variation in the IL-1 gene cluster is not fully resolved.

Psoriatic arthritis. A subsequent Su et al. (2018) multi-disease meta-analysis⁵⁵ Su et al. (2018) multi-disease meta-analysis
Meta-analyses of IL1A polymorphisms and the risk of several autoimmune diseases published in databases. PLoS One 2018 found significant association of rs17561 with psoriatic arthritis (PA) specifically, while failing to find associations with RA, systemic sclerosis, SLE, or multiple sclerosis, suggesting a disease-specific rather than pan-autoimmune effect.

The Ser allele is substantially more common in Europeans (~30% allele frequency) and South Asians (~31%) compared to East Asians (~8%), which may partly explain why associations have primarily been documented in Caucasian cohorts.

Practical Actions

The A allele at rs17561 (Ser form, hypomorphic) is associated with reduced IL-1α alarmin signalling — meaning the variant's consequences manifest most prominently at barriers where this cytokine provides first-line surveillance: the periodontium and possibly the mucosal interfaces of the gut and joints. For carriers of one or two A alleles, the most actionable implications are: heightened attention to periodontal health (where the association is most directly supported) and awareness of the modest but significant IL1A locus contribution to ankylosing spondylitis susceptibility.

Anti-IL-1 biologic therapy (anakinra, canakinumab) is used in AS and certain autoinflammatory disorders. Carriers of the Ser hypomorph naturally have lower IL-1α output; this may be relevant to patient stratification in clinical trials of IL-1 pathway therapies, though personalised dosing based on rs17561 genotype is not yet established practice.

Interactions

IL1B rs1143634 and IL1RN rs2234663: IL-1α and IL-1β both signal through the IL-1 receptor (IL-1R1) and are co-expressed in inflamed tissues. IL-1 receptor antagonist (IL-1Ra, encoded by IL1RN) competitively inhibits both. Carriers of the IL1A Ser hypomorph (reduced IL-1α) combined with variants that increase IL-1β production or reduce IL-1Ra levels may have net IL-1 pathway activity that differs substantially from either variant alone — the overall alarmin balance is shaped by all three loci together.

IL1A rs1800587 (–889 C/T): A second functionally characterised IL1A variant in the proximal promoter (rs1800587) modulates IL1A transcription. The two variants are independent (rs17561 is exonic, rs1800587 is promoter) and potentially additive in their effects on IL-1α output. rs1800587 was associated with Graves' disease risk in the Su et al. meta-analysis. Carriers of risk alleles at both loci would have additive reductions in IL-1α availability.

IL1A rs6542095: A third IL1A variant with GWAS-level evidence for moderate-to-severe endometriosis susceptibility. rs6542095 and rs17561 are in different positions on chromosome 2q13 and likely independent.

Prothrombin — also called coagulation Factor II — is the precursor to thrombin, the central enzyme that converts fibrinogen into fibrin clot. The G20210A mutation in the prothrombin gene (F2) doesn't change the structure of prothrombin itself; instead, it quietly turns up its production. Carriers make 30% more prothrombin¹¹ 30% more prothrombin
Plasma prothrombin levels measured in multiple studies; homozygotes produce roughly 70% above baseline than the average person, and that excess shifts the coagulation balance toward clotting. This makes G20210A the second most common inherited thrombophilia²² second most common inherited thrombophilia
After Factor V Leiden, which affects approximately 5% of Europeans; G20210A affects 1-3% in people of European descent, with a carrier frequency of 1-3% in this population.

The Mechanism

The G20210A variant sits at position 20210 in the 3' untranslated region (3' UTR)³³ 3' untranslated region (3' UTR)
The non-coding tail of mRNA that controls stability, export, and how efficiently the message is translated into protein of the F2 gene on chromosome 11. This is the final nucleotide before the polyadenylation signal — the molecular "stop" marker that terminates mRNA. Replacing guanine with adenine at this position creates a more efficient cleavage site for the RNA processing machinery. The result is enhanced 3' end processing, more stable mRNA, and greater protein output⁴⁴ enhanced 3' end processing, more stable mRNA, and greater protein output
Functional studies by Gehring et al. confirmed enhanced polyadenylation efficiency is the core mechanism. Prothrombin plasma levels rise 30% in heterozygotes and approximately 70% in the rare homozygotes.

More prothrombin in circulation means more thrombin available whenever coagulation is triggered, lowering the threshold for clot formation without directly disrupting the normal regulatory mechanisms. The coagulation system becomes hair-triggered — adequate for normal hemostasis but prone to excessive clotting under provocation (surgery, immobility, hormonal changes, pregnancy).

The Evidence

The variant was first described in 1996 by Poort and colleagues⁵⁵ first described in 1996 by Poort and colleagues
Seminal paper in Blood identifying G20210A in 28% of families with unexplained venous thrombosis. The original cohort showed a 2.8-fold increased risk of VTE in heterozygous carriers, and this estimate has held up across decades of replication.

A pooled analysis of 8 case-control studies⁶⁶ pooled analysis of 8 case-control studies
2,310 VTE cases and 3,204 controls; Study Group for Pooled-Analysis in Venous Thromboembolism established that the interaction with Factor V Leiden is clinically critical: double heterozygotes — carrying both G20210A and the Factor V Leiden mutation (rs6025) — face an odds ratio of 20 for venous thromboembolism, versus 3.8 for G20210A alone. A more recent FinnGen and UK Biobank analysis of 26,000+ carriers⁷⁷ FinnGen and UK Biobank analysis of 26,000+ carriers
Published in Blood 2024 estimated the double-heterozygote OR at 5.24, suggesting the classical 20-fold estimate from smaller studies was inflated — but even the conservative biobank estimate represents an enormous absolute risk elevation.

The interaction with combined oral contraceptives (estrogen-containing pills)⁸⁸ combined oral contraceptives (estrogen-containing pills)
OC use independently increases VTE risk 3-5 fold through increased coagulation factor production and reduced fibrinolysis is particularly clinically important. Women carrying G20210A who use combined oral contraceptives face an estimated 6- to 16-fold elevated VTE risk compared to non-carriers not using OCs. Progestin-only pills and non-hormonal methods (copper IUD, levonorgestrel IUD) do not carry this additional risk.

For recurrent VTE risk⁹⁹ recurrent VTE risk
Meta-analysis of prospective studies through 2024, heterozygous carriers who have already experienced one VTE event face a 79% increased risk of recurrence compared to non-carriers.

Practical Implications

The actionable implications of this variant fall into three categories. First, women of reproductive age should discuss contraception choices with their physician — estrogen-containing methods carry elevated risk that is specific and avoidable. Second, any known carrier facing elective surgery, prolonged immobility (long-haul flights, hospitalization), or major hormonal changes (pregnancy, postpartum) should have this documented in their medical record and discuss thromboprophylaxis with their doctor. Third, first-degree relatives of a carrier have a 50% chance of carrying the same variant and may benefit from testing, especially before events that trigger thrombosis.

Anticoagulation after a first VTE event is managed the same way regardless of G20210A carrier status — typically 3-6 months of anticoagulation for provoked events, longer for unprovoked. The G20210A status is most relevant for the recurrence risk discussion and whether extended anticoagulation is warranted.

Interactions

The most clinically important interaction is with Factor V Leiden (rs6025, F5 R506Q)¹⁰¹⁰ Factor V Leiden (rs6025, F5 R506Q)
Factor V Leiden is the most common inherited thrombophilia, present in 5% of Europeans; double heterozygosity compounds risk multiplicatively. A person carrying both G20210A and Factor V Leiden has coagulation hyperactivated at two independent checkpoints simultaneously, producing far greater risk than either variant alone. This double heterozygous combination should be flagged as a high-priority compound interaction.

Acquired thrombophilic states — antiphospholipid syndrome, cancer, nephrotic syndrome, polycythemia vera — compound with inherited thrombophilias including G20210A in an additive or synergistic manner. The number of 20210A alleles carried (0, 1, or 2) also matters: homozygotes face substantially higher risk than heterozygotes, though homozygosity is rare (approximately 0.01% of Europeans).